Endocyte, Inc.
Apr 2, 2014
PDF
Add to Briefcase

Endocyte, Inc. Closes Public Offering of Common Stock

WEST LAFAYETTE, Ind., April 2, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) announced today the closing of its previously announced underwritten public offering of 5,175,000 shares of its common stock at a price to the public of $21.00 per share, which includes the exercise in full by the underwriters of their option to purchase 675,000 additional shares. Endocyte received net proceeds of approximately $101.8 million from the offering after deducting underwriting discounts and commissions and estimated expenses relating to the offering.

Credit Suisse and Citigroup served as joint book-running managers, Cowen and Company served as lead manager, and RBC Capital Markets, Baird, Wedbush PacGrow Life Sciences and Roth Capital Partners served as co-managers. The offering was conducted as a public offering under the company's shelf registration statement filed with the Securities and Exchange Commission. The offering was made only by means of the prospectus supplement and accompanying prospectus.

Copies of the prospectus supplement and accompanying prospectus for this offering can be obtained by contacting: Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, or by telephone at (800) 221-1037, or by e-mail at newyork.prospectus@credit-suisse.com; or Citigroup Global Markets Inc. c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, by email at batprospectusdept@citi.com or by phone at (800) 831-9146.

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company's SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment.

CONTACT: Stephanie Ascher, Stern Investor Relations, Inc.,

         (212) 362-1200, stephanie@sternir.com



         Martina Schwarzkopf, Ph.D., Russo Partners,

         (212) 845-4292, martina.schwarzkopf@russopartnersllc.com



         Tony Russo, Ph.D., Russo Partners,

         (212) 845-4251, tony.russo@russopartnersllc.com

Endocyte logo

Source: Endocyte, Inc.

News Provided by Acquire Media